In this platinum-pretreated population of advanced UC, the addition of vandetanib to docetaxel did not result in a significant improvement in PFS, ORR, or OS. The toxicity of vandetanib plus docetaxel was greater than that for vendetanib plus placebo. Single-agent vandetanib activity was minimal.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Dana-Farber Cancer Institute, Boston, MA 02215, USA. Toni_Choueiri [at] dfci.harvard.edu
J Clin Oncol. 2012 Feb;30(5):507-12
© Galenicom 1999-2013